Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) have earned a consensus rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $3.33.

Several equities analysts have recently issued reports on the stock. BidaskClub raised shares of PDL BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $4.00 price target on shares of PDL BioPharma in a research note on Thursday, August 10th. Zacks Investment Research raised shares of PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Wednesday, August 16th. ValuEngine raised shares of PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Finally, Cowen and Company reissued a “hold” rating and set a $3.00 target price on shares of PDL BioPharma in a research note on Friday, October 27th.

ILLEGAL ACTIVITY WARNING: “PDL BioPharma, Inc. (PDLI) Receives $3.33 Average Price Target from Brokerages” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/pdl-biopharma-inc-pdli-receives-3-33-average-price-target-from-brokerages/1712797.html.

Shares of PDL BioPharma (PDLI) traded down $0.01 during trading hours on Monday, reaching $2.84. 988,229 shares of the company traded hands, compared to its average volume of 1,849,973. The company has a market cap of $439.87, a P/E ratio of 5.88 and a beta of 0.46. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.90 and a current ratio of 1.94. PDL BioPharma has a fifty-two week low of $1.93 and a fifty-two week high of $3.55.

PDL BioPharma (NASDAQ:PDLI) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.01. The firm had revenue of $62.75 million during the quarter, compared to the consensus estimate of $61.86 million. PDL BioPharma had a net margin of 24.51% and a return on equity of 9.33%. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 earnings per share. equities analysts predict that PDL BioPharma will post 0.67 earnings per share for the current fiscal year.

PDL BioPharma announced that its board has approved a share repurchase program on Monday, September 25th that authorizes the company to repurchase $25.00 million in shares. This repurchase authorization authorizes the biotechnology company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.

A number of large investors have recently bought and sold shares of the business. California Public Employees Retirement System grew its holdings in PDL BioPharma by 12.2% in the third quarter. California Public Employees Retirement System now owns 1,085,093 shares of the biotechnology company’s stock worth $3,678,000 after purchasing an additional 117,993 shares during the period. Cubist Systematic Strategies LLC grew its holdings in PDL BioPharma by 64.0% in the third quarter. Cubist Systematic Strategies LLC now owns 49,062 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 19,144 shares during the period. Highbridge Capital Management LLC grew its holdings in PDL BioPharma by 562.4% in the third quarter. Highbridge Capital Management LLC now owns 132,477 shares of the biotechnology company’s stock worth $449,000 after purchasing an additional 112,477 shares during the period. Allianz Asset Management GmbH grew its holdings in PDL BioPharma by 18.5% in the third quarter. Allianz Asset Management GmbH now owns 941,088 shares of the biotechnology company’s stock worth $3,191,000 after purchasing an additional 146,817 shares during the period. Finally, Mackenzie Financial Corp grew its holdings in shares of PDL BioPharma by 39.0% during the third quarter. Mackenzie Financial Corp now owns 5,074,015 shares of the biotechnology company’s stock valued at $17,201,000 after buying an additional 1,423,471 shares during the last quarter. Institutional investors and hedge funds own 83.38% of the company’s stock.

About PDL BioPharma

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.